A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer